Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYTOIN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Generalized tonic-clonic seizures (grand mal epilepsy),Complex partial seizures (psychomotor/temporal lobe seizures),Prevention and treatment of seizures occurring during or following neurosurgery,Status epilepticus (intravenous formulation)
Mild to moderate pain,Fever
Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Average terminal half-life 22 hours (range 7–42 hours) in adults; dose-dependent due to saturation of metabolism at therapeutic concentrations (10–20 mg/L). Half-life increases with higher doses.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Phenytoin is extensively metabolized in the liver primarily by the cytochrome P450 enzyme CYP2C9, with minor contributions from CYP2C19. The major metabolite is the glucuronide conjugate of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH). Phenytoin exhibits dose-dependent, saturable (Michaelis-Menten) pharmacokinetics.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily hepatic metabolism (>95%); less than 5% excreted unchanged in urine. Renal excretion of metabolites (glucuronides) accounts for ~80% of elimination; biliary/fecal excretion of metabolites ~20%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
90–95% bound, primarily to albumin; binding is saturable and decreases in hypoalbuminemia, uremia, or with other highly bound drugs.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.6–0.8 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier; Vd increases in neonates and decreases in renal failure.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 90–100% (phenytoin sodium extended-release); IM: low and erratic (not recommended) due to precipitation and slow absorption.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No specific GFR-based adjustment required; use with caution in severe renal impairment (GFR < 10 m L/min) due to protein binding changes.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 25-50%; Child-Pugh C: Reduce dose by 50-75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Loading dose: 15-20 mg/kg IV/PO; Maintenance: 5-10 mg/kg/day PO in 2-3 divided doses.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at low end of dosing range (e.g., 3 mg/kg/day); monitor for toxicity; consider reduced protein binding and slower metabolism.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Intravenous administration of phenytoin is associated with serious cardiovascular adverse reactions including severe hypotension and cardiac arrhythmias (e.g., bradycardia, heart block, ventricular fibrillation). These reactions can occur more frequently in patients with advanced age, known cardiac disease, or those receiving other medications that affect the cardiovascular system. Continuous monitoring of ECG and vital signs is required during IV administration, and the rate of infusion should not exceed 50 mg/min in adults.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Cardiovascular risk during IV administration (see black box warning),Hypersensitivity reactions: Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS),Hepatic injury: Acute hepatotoxicity, including elevated liver enzymes and hepatitis,Hematologic effects: Agranulocytosis, thrombocytopenia, leukopenia, pancytopenia,Central nervous system effects: Nystagmus, ataxia, slurred speech, mental confusion, dizziness, drowsiness,Hyperglycemia: May elevate blood glucose levels,Osteomalacia and hypocalcemia due to altered vitamin D metabolism,Teratogenicity: Fetal hydantoin syndrome (craniofacial abnormalities, growth deficiency, intellectual disability),Birth defects: Increased risk of cardiovascular malformations and neural tube defects,Carcinogenicity: Long-term use associated with increased risk of malignancies (lymphoma, hepatocellular carcinoma)
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation,Sinus bradycardia, sinoatrial block, second- or third-degree AV block, Adams-Stokes syndrome,Concurrent use with delavirdine (due to decreased delavirdine concentrations),History of prior acute hepatotoxicity attributable to phenytoin,Porphyria (may precipitate acute attacks)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Enteral tube feedings can decrease phenytoin absorption; hold feeds 1-2 hours before and after administration. High-fat meals may increase absorption consistency. Folic acid supplementation may lower phenytoin levels. Calcium supplements and antacids can impair absorption; separate by 2-3 hours.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during first trimester (organogenesis). Second and third trimester exposure may cause impaired fetal growth, microcephaly, and neurodevelopmental delay. Risk of major malformations is dose-dependent and increases with polytherapy.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Phenytoin is excreted into breast milk with estimated infant dose of 2-10% of maternal weight-adjusted dose; M/P ratio approximately 0.18-0.45. Generally considered compatible with breastfeeding; monitor infant for drowsiness, poor feeding, and rash. Avoid if maternal dose >400 mg/day or signs of infant toxicity.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy decreases phenytoin concentrations due to increased clearance (hepatic induction, increased Vd, decreased albumin). Dose adjustments are frequently required: increase total daily dose by 30-50% on average, guided by free phenytoin concentrations (target 1-2 mcg/m L). Monitor serum levels every 2-4 weeks, especially in third trimester. Postpartum, dose should be reduced to prepregnancy levels over 1-2 weeks to avoid toxicity.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Phenytoin exhibits zero-order kinetics at therapeutic levels; small dose increases can cause toxicity. Monitor free phenytoin levels in hypoalbuminemia or uremia. Fosphenytoin is a prodrug used for IV loading with fewer infusion-site reactions. Caution in CYP2C9 poor metabolizers; consider genetic testing. May cause folate deficiency, peripheral neuropathy, and osteomalacia with long-term use. Co-administration with valproate displaces phenytoin from protein binding, increasing free fraction.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not skip doses or change brands without consulting your doctor.,Do not stop taking suddenly as this may cause withdrawal seizures.,Avoid alcohol as it can affect drug levels and increase side effects.,Report any rash, fever, swollen glands, or mouth sores immediately (risk of Stevens-Johnson syndrome).,Use reliable contraception if sexually active; phenytoin reduces effectiveness of hormonal contraceptives.,Maintain good dental hygiene and see dentist regularly; may cause gum overgrowth.,Take with food if stomach upset occurs, but avoid high-fat meals if consistent timing is needed.,May cause dizziness, drowsiness, or blurred vision; avoid driving until you know how it affects you.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Phenytoin is a potent inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes. Dasatinib is primarily metabolized by CYP3A4. Coadministration with phenytoin significantly reduces dasatinib plasma concentrations, potentially leading to subtherapeutic levels, reduced efficacy, and increased risk of disease progression in chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia."
"Phenytoin, a known inducer of CYP450 enzymes (particularly CYP3A4 and CYP2C9), increases the hepatic metabolism of ambroxol, a mucolytic agent primarily metabolized via CYP3A4. This induction reduces ambroxol plasma concentrations, potentially diminishing its therapeutic efficacy in clearing respiratory secretions. Clinically, patients may experience reduced mucolytic effects, leading to inadequate clearance of bronchial secretions and worsening of underlying respiratory conditions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYTOIN vs ACEPHEN, answered by our medical review team.
PHENYTOIN is a Anticonvulsant that works by Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYTOIN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYTOIN is: Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENYTOIN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENYTOIN is classified as Category D/X. Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during f. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.